

AUSTRALIAN PATENT ISSUED IN CORE PATENT FAMILY

- Australian Patent no 2011292809 issued
- Patent family provides protection for BARD1 Lung Cancer Test

Perth, Australia, 7 August 2017: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) today announced that on 28th July 2017, IP Australia issued Australian Patent number 2011292809 titled “BARD1 isoforms in lung and colorectal cancer and use thereof”.

This patent family protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, a method for detecting the presence of the specific BARD1 isoforms, and a method for treating and/or preventing lung cancer and colorectal cancer. The patent was filed in the name of Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17th August 2011 and expires on 17th August 2031. BARD1 LSL (via its fully owned subsidiary BARD1AG SA) has licensed the commercial rights to exploit this technology from UNIGE and HUG.

BARD1 LSL CEO, Dr Leearne Hinch commented: “This core patent family now has 4 granted patents in the US, Japan, China and Australia, with other jurisdictions pending. The BARD1 LSL patent portfolio includes 5 patent families covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers.”

The BARD1 Lung Cancer Test is currently in development for the early detection of lung cancer. Lung cancer is the fifth most common cancer and the leading cause of cancer deaths in Australia. The Australian Institute of Health and Welfare (AIHW) estimates that there will be 12,434 new cases of lung cancer diagnosed (9.3% of all new cancers diagnosed) and 9,021 deaths from lung cancer (18.9% of all cancer deaths) in Australia in 2017¹. Lung cancer is often diagnosed at a later stage after it has spread to other parts of the body, resulting in a 16% chance of survival after 5-years in Australia. Early detection of lung cancer has the potential to save people’s lives by enabling earlier treatment when it is potentially curable. There is currently no approved blood test available for early detection of lung cancer in people without symptoms.

- ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg
Chairman
E peter@bard1.com

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. Its lead product, the BARD1 Lung Cancer Test, is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm. The company’s pipeline also includes the BARD1 Ovarian Cancer Test in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research-stage for multiple cancers. BARD1 LSL is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

¹ AIHW 2017. Lung cancer – Lung cancer in Australia. Available <http://www.aihw.gov.au/cancer/lung/>, accessed Jul 19, 2017.

ABOUT THE BARD1 INTELLECTUAL PROPERTY PORTFOLIO

BARD1 LSL has established a strong intellectual property portfolio covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers. The patent portfolio comprises 5 patent families with multiple granted and pending patents across key marketplaces including the US, Europe, Japan and other countries.

Patent Family	Title	Status		Expiry
		Granted	Pending	
PCT/FR01/02731	Truncated BARD1 protein and its diagnostic and therapeutic uses	US, JP		2023*
PCT/IB2011/053635	BARD1 isoforms in lung and colorectal cancer and use thereof	US, JP, CN, AU	US, JP, CN (divisionals), EP, CA, IL, BR, SG	2031*
PCT/IB2011/054194	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof		US, EP	2032*
PCT/EP2014/073834	Lung Cancer Diagnosis		US, EP, CA, JP, IL, CN, AU, SG, KR	2034*
EP14002398.7	Novel non-coding RNA, cancer target and compounds for cancer treatment		US	2035*

* Plus any extension of term in the US due to prosecution delay